Výsledky vyhledávání

Akademický článek

Power law between the apparent drainage density and the pruning area

Autor: S. Yang, K. Choi, K. Paik

Publikováno v: Hydrology and Earth System Sciences, Vol 28, Pp 3119-3132 (2024)

Self-similar structures of river networks have been quantified as having diverse scaling laws. Among these, we investigated a power function relationship between the apparent drainage density ρa and the pruning area Ap, with an exponent η. We analy

Externí odkaz: https://doaj.org/article/1f35e1e1f2e842c4a68e583fea4d37e3

Zobrazit plný text záznamu

Akademický článek

Simulating the evolution of the topography–climate coupled system

Autor: K. Paik, W. Kim

Publikováno v: Hydrology and Earth System Sciences, Vol 25, Pp 2459-2474 (2021)

Landscape evolution models simulate the long-term variation of topography under given rainfall scenarios. In reality, local rainfall is largely affected by topography, implying that surface topography and local climate evolve together. Herein, we dev

Externí odkaz: https://doaj.org/article/71fc9be6099b4d9f9c4d6ee8999a0718

Zobrazit plný text záznamu

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Autor: Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Franziska Michor, Helena A. Yu

Publikováno v: Clinical Cancer Research. 29:1423-1428

Purpose: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54f4f625ed5f97d1b7e414751e5f95a4
https://doi.org/10.1158/1078-0432.ccr-22-3484

Zobrazit plný text záznamu

Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Autor: Paul K Paik, Ravi K Goyal, Beilei Cai, Mark A Price, Keith L Davis, Valerie Derrien Ansquer, Nydia Caro, Teddy R Saliba

Publikováno v: Future Oncology. 19:217-228

Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Material

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f8beb36594f1412c9850d5daf4732bc
https://doi.org/10.2217/fon-2022-1133

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání